As shown in Fig. 3, patients with high PODXL expression in their pre-neoadjuvant biopsies had a superior histopathologic response (notably 36% with no residual cancer cells) compared to those with negative (p = 0.010) or low (p = 0.013) PODXL expression. The gene discussed is PODXL; the disease is cancer.